In patient-derived xenografts models from patients with heavily pre-treated ovarian cancer, THZ1 (a chemical that inhibits CDK7, CDK12, and CDK13) repressed MYC expression and suppressed tumor growth. Here, CDK13 is linked to neoplasm.